(Q43001884)

12 November 2017

Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo (English)

1 reference

12 November 2017

9

1 reference

12 November 2017

5

Pim van der Harst

0 references

Dirk J van Veldhuisen

8

object named as

Dirk J van Veldhuisen

1 reference

12 November 2017

Irma Kuipers

1

1 reference

12 November 2017

Jiang Li

2

1 reference

12 November 2017

Inge Vreeswijk-Baudoin

3

1 reference

12 November 2017

Johan Koster

4

1 reference

12 November 2017

Pim van der Harst

5

1 reference

12 November 2017

Herman H W Silljé

6

1 reference

12 November 2017

Folkert Kuipers

7

1 reference

12 November 2017

Rudolf A de Boer

10

1 reference

12 November 2017

29 June 2010

1 reference

European Journal of Heart Failure

12 November 2017

1 reference

12 November 2017

12

1 reference

12 November 2017

10

1 reference

12 November 2017

1042-1050

1 reference

Cardiac hypertrophy: the good, the bad, and the ugly

12 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Acute neurohumoral modulation of diastolic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Metabolic remodelling of the failing heart: beneficial or detrimental?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Interleukin-1 beta induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

With great power comes great responsibility: using mouse genetics to study cardiac hypertrophy and failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Liver X receptors alpha and beta regulate renin expression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Nuclear hormone receptors as regulators of the renin-angiotensin-aldosterone system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

LXR signaling couples sterol metabolism to proliferation in the acquired immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Identification and characterization of two alternatively spliced transcript variants of human liver X receptor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Role of LXRs in control of lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Liver x receptors: potential novel targets in cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Activation of liver X receptor-alpha reduces activation of the renal and cardiac renin-angiotensin-aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Activation of liver X receptors and retinoid X receptors induces growth arrest and apoptosis in insulin-secreting cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Oxysterol stimulation of epidermal differentiation is mediated by liver X receptor-beta in murine epidermis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

The oxysterol receptor LXR inhibits proliferation of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Liver X receptor agonist GW3965 dose-dependently regulates lps-mediated liver injury and modulates posttranscriptional TNF-alpha production and p38 mitogen-activated protein kinase activation in liver macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ109

21 January 2018

Identifiers

DOI

10.1093/EURJHF/HFQ109

1 reference

12 November 2017

1 reference